DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Bausch - 5 Jim Cramer - 4 Jim - 4 Jim Cramer's - 4 Xifaxan - 2 Jefferies - 2 BHC - 2 Scott Olson - 1
Top related locs:
CHICAGO , ILLINOIS Chicago , Illinois BLCO Wells Fargo BlackRock New York U.S Interphex
Top related orgs:
Health - 5 Bausch Health - 4 CNBC - 4 Jefferies - 3 Citigroup - 2 GE Healthcare - 2 Getty - 2 New York Stock Exchange - 1

Search resuls for: "Bausch Health's"


9 mentions found


☆ Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
  + stars: | 2024-09-17 | by ( Kenneth Squire | ) www.cnbc.com   time to read: +7 min
Bausch + Lomb parent company Bausch Health is spinning off the eye-care company with an upcoming IPO which will list on the New York Stock Exchange and TSX with the ticker symbol “BLCO”. This would greatly benefit BLCO stockholders, of which Bausch Health is the largest. As an 88% owner of BLCO, Bausch Health's value derived from such a sale would be $12.32 billion. Adding the value of the proceeds from BLCO sale, the Xifaxan cash flows and RemainCo yields a total value of $25.93 billion for Bausch Health. After subtracting 100% of the Bausch Health debt, that would yield an equity value of $10.49 billion or $28.19 per share.
Persons: Bausch, Scott Olson, Richard Mulligan, John Paulson, Brett Icahn, Steven Miller, Carl Icahn, BLCO, Goldman Sachs, Bausch Health's, Peers, InMode, Takeda, Gary Hu, Brent Saunders, Ken Squire Organizations: Bausch Health, New York Stock Exchange, TSX, U.S . Securities, Exchange, Financial Times, Cooper Companies, BLCO, Products, Takeda Pharmaceuticals, Ironwood Pharmaceuticals, Health, 13D Locations: CHICAGO , ILLINOIS, Chicago , Illinois, BLCO
☆ Morgan Stanley tumbles, GE Healthcare climbs — what's driving Thursday's major portfolio stock moves
  + stars: | 2024-04-11 | by ( Jeff Marks | ) www.cnbc.com   time to read: +5 min
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.
Persons: Jim Cramer, Stocks, Banks, JPMorgan Chase, Jamie Dimon, Morgan Stanley, Bausch, Jim, Jim Cramer's Organizations: CNBC, Club, Citigroup, JPMorgan, Securities and Exchange Commission, U.S, Appeals, Federal Circuit, Health, Jefferies, Xifaxan, Bausch Health, Costco, GE Healthcare, Mizuho, Broadcom, Apple, Nvidia, Jim Cramer's Charitable Locations: Wells Fargo, BlackRock
☆ We're trimming an embattled portfolio stock facing a binary event that could go either way
  + stars: | 2024-02-29 | by ( Jeff Marks Jim Cramer | Jeff Marks | Jim Cramer | ) www.cnbc.com   time to read: +4 min
Following Thursday's trade, Jim Cramer's Charitable Trust will own 2,930 shares of BHC, decreasing its weighting in the portfolio to 0.82% from 1.1%. We're trimming roughly one-quarter of our Bausch Health position to manage our downside risk ahead of a key event. As the likelihood of monetizing its BLCO stake increases, BHC shares are expected to trade appreciably higher. BHC 1Y mountain Bausch Health Companies 1 year What we have on our hands is a binary situation and the outcome could go either way. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.
Persons: Jim Cramer's, Xifaxan, Bausch, Jefferies, BHC, Johnson, haven't, we've, It's, Jim Cramer, Jim Organizations: Bausch Health, Jefferies, Health, CNBC
☆ Bausch Health's decent quarter can't overcome headwind of ongoing patent dispute
  + stars: | 2023-11-02 | by ( Zev Fima | ) www.cnbc.com   time to read: +4 min
But they aren't enough to overcome the headwind of the company's ongoing patent legislation. Good numbers, but they take a back seat to the legal battle over Bausch drug Xifaxan. Management didn't provide any update on timing for when the remaining 88% of BLCO that Bausch Health owns will be sold off. Management now expects companywide EBITDA in a range of $3.01 to $3.11 billion, versus an earlier range of $3.0 to $3.15 billion. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Bausch, Xifaxan, BCH's Bausch, companywide, Jim Cramer's, Jim Cramer, Jim, Timothy Fadek Organizations: Health, Revenue, Pharmaceuticals, Norwich Pharmaceuticals, D.C, Norwich, FDA, XIFAXAN, Management didn't, Bausch Health, Management, CNBC, International Pharmaceutical, Bloomberg, Getty Images Bloomberg, Getty Locations: New York, U.S, Interphex
☆ Health care has had a tough year. Where we stand on our 5 stocks in the sector
  + stars: | 2023-09-22 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +12 min
Bausch Health (BHC) is a different case. Key points Health-care stocks outperformed the broader U.S. stock market last year, but this year it's been much-tougher sledding for the sector due to a variety of headwinds. We feel comfortable owning our three other primary health care stocks: GE Healthcare, Humana and Danaher. In recent weeks, analysts at Wells Fargo and Citigroup have started coverage of GE Healthcare with buy ratings. The analysts at Jefferies now rate Bausch Health stock a buy, with a price target increase to $16 per share from $9.
Persons: There's Eli Lilly, Eli Lilly, That's, Eli Lilly's, Ryan Issakainen, we're, Issakainen, –, Stryker, Jim Cramer, it's, Jim, We've, Bausch, BHC, We're, I'm, Jefferies, Jim Cramer's, Frederick Florin Organizations: GE Healthcare, Health, Federal Reserve, First Trust Advisors, Humana, Medicare, Dow, UnitedHealth, GE, General Electric, —, Citigroup, Jefferies, CNBC, AFP, Getty Locations: what's, China, STE, Biogen, Wells, Bausch, Fegersheim, France
☆ Bausch Health's quarter disappoints, guidance beats. But uncertainty prevails over patent litigation
  + stars: | 2023-05-04 | by ( Zev Fima | ) www.cnbc.com   time to read: +5 min
Xifaxan sales were also up 7%. Internationally, reported Q1 sales of $247 million missed estimates but grew 1% compared to the year-ago period. Organic sales grew 5%, driven by strength in Canada and Europe. Organic sales grew 6%. Excluding Bausch + Lomb, the team reiterated their revenue guidance of $4.45 billion to $4.6 billion, as well as their adjusted EBITDA guidance of $2.3 billion to $2.4 billion.
☆ These 10 fairly priced stocks are well off recent highs. Here's where we stand on them
  + stars: | 2023-04-05 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +8 min
52-week high date: April 5, 2022 Percent below 52-week high: 68.4% Forward P/E: 2.1 We continue to view troubled Bausch Health as a wait-and-see situation. CTRA 1Y mountain Coterra's stock performance over the past 12 months. 52-week high date: May 31, 2022 Percent below 52-week high: 26.94% Forward P/E: 9.5 Our view on Pioneer Natural Resources (PXD) is similar to Coterra. 52-week high date: June 8, 2022 Percent below 52-week high: 24.46% Forward P/E: 10.4 Like our two other energy stocks, we want to see another pullback in Halliburton shares before we'd add to our position. 52-week high date: Jan. 27, 2023 Percent below 52-week high: 18.26% Forward P/E: 13.4 Caterpillar is a beaten-down stock worth buying.
☆ Bausch Health's stock soars on solid quarterly results, but we have concerns about the recovery
  + stars: | 2023-02-23 | by ( Zev Fima | ) www.cnbc.com   time to read: +4 min
Bottom line The Canadian specialty pharmaceuticals company reported solid results for the fourth quarter, along with favorable forward guidance. Bausch management on Thursday did not offer additional information, other than to reiterate its confidence in the strength of the company's patents. Bausch Health previously started the separation process via an initial public offering of Bausch + Lomb in May 2022. Results at the diversified products division — which includes neurology pharmaceutical products, generics and dentistry products — were hampered by generic competition. Notably, as Bausch Health owns most of Bausch + Lomb, the latter's financials still appear on Thursday's results.
☆ 4 of our stocks are in the news. Here's the Club's take on each development
  + stars: | 2022-11-03 | by ( Jeff Marks | ) www.cnbc.com   time to read: +11 min
Four of our Club holdings — Costco Wholesale (COST), Amazon (AMZN), Humana (HUM) and Bausch Health (BHC) — were in the news Thursday. Bausch Health The news: Bausch Health reported third-quarter results before the opening bell Thursday. Given the latter's roughly $4.73 billion market capitalization, Bausch Health's stake is worth approximately $4.2 billion. The reason behind Bausch Health trading consistently below the valuation of its BLCO stake is debt. Secured debt means that Bausch Health has put up assets as collateral, meaning in the event of default the lenders take ownership of the collateralized assets.
0 next >>
Total: 9